Diversity of lipid-based polyene formulations and their behavior in biological systems View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-01

AUTHORS

K. M. Wasan, G. Lopez-Berestein

ABSTRACT

Patients with cancer and infectious diseases often display dyslipidemias that result in changes in their plasma lipoprotein-lipid composition. It is likely that the interactions of liposomal polyenes with plasma lipoproteins may be responsible for the far different pharmacokinetics and pharmacodynamics of these compounds when they are administered to infected patients rather than to animals or healthy volunteers. Amphotericin B (AmpB) and nystatin are examples of such polyenes. Amphotericin B initially distributes with the high-density lipoprotein (HDL) fraction upon incubation in plasma. Over time, AmpB redistributes from HDLs to low-density lipoproteins (LDLs). This redistribution appears to be regulated by lipid transfer protein. However, when AmpB is incorporated into liposomes composed of negatively or positively charged phospholipids, not only is the capability of LTP to transfer AmpB from HDL to LDL diminished, but AmpB remains retained with only the HDL fraction. However, when liposomal nystatin is incubated in plasma, over 50% of nystatin distributes with HDLs. Over time, nystatin redistributes from HDL to the lipoprotein-deficient plasma fraction, which is composed of mainly aqueous plasma proteins. The lipid composition selected for the drug appears to be a vital constituent in regulating the drug's interaction with biological fluids. Furthermore, liposome (or liposomal particle) size, fluidity, and other physiochemical characteristics also play a role in altering the pharmacokinetics and pharmacological effects of lipid-based drug formulations. Armed with this understanding, a rational approach to clinical development of these formulations could be facilitated. More... »

PAGES

81-92

References to SciGraph publications

  • 1990-06. Interaction of lipid transfer protein with plasma lipoproteins and cell membranes in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 1992-10. Liposomal and Lipid Formulations of Amphotericin B in CLINICAL PHARMACOKINETICS
  • 1986-10. Peroxidised linoleic acid and experimental pancreatitis in JOURNAL OF GASTROINTESTINAL CANCER
  • 1983-12. Site–Specific (Targeted) Drug Delivery in Cancer Therapy in NATURE BIOTECHNOLOGY
  • 1982. Antibody-Mediated Targeting of Liposomes in TARGETING OF DRUGS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf01575125

    DOI

    http://dx.doi.org/10.1007/bf01575125

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1053583750

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9063678


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1101", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Biochemistry and Metabolomics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Amphotericin B", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anti-Bacterial Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antifungal Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunocompromised Host", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lipoproteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liposomes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mycoses", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nystatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phagocytes", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, V6T 1Z3, Vancouver, British Columbia, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17091.3e", 
              "name": [
                "Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, V6T 1Z3, Vancouver, British Columbia, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wasan", 
            "givenName": "K. M.", 
            "id": "sg:person.0666655515.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666655515.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Section of Immunobiology and Drug Carriers, Department of Bioimmunotherapy, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Section of Immunobiology and Drug Carriers, Department of Bioimmunotherapy, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lopez-Berestein", 
            "givenName": "G.", 
            "id": "sg:person.0650504273.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650504273.00"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nbt1283-869", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026993837", 
              "https://doi.org/10.1038/nbt1283-869"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4684-4241-0_11", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041284496", 
              "https://doi.org/10.1007/978-1-4684-4241-0_11"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01939693", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040111814", 
              "https://doi.org/10.1007/bf01939693"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02795249", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023737788", 
              "https://doi.org/10.1007/bf02795249"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-199223040-00004", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041292032", 
              "https://doi.org/10.2165/00003088-199223040-00004"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1997-01", 
        "datePublishedReg": "1997-01-01", 
        "description": "Patients with cancer and infectious diseases often display dyslipidemias that result in changes in their plasma lipoprotein-lipid composition. It is likely that the interactions of liposomal polyenes with plasma lipoproteins may be responsible for the far different pharmacokinetics and pharmacodynamics of these compounds when they are administered to infected patients rather than to animals or healthy volunteers. Amphotericin B (AmpB) and nystatin are examples of such polyenes. Amphotericin B initially distributes with the high-density lipoprotein (HDL) fraction upon incubation in plasma. Over time, AmpB redistributes from HDLs to low-density lipoproteins (LDLs). This redistribution appears to be regulated by lipid transfer protein. However, when AmpB is incorporated into liposomes composed of negatively or positively charged phospholipids, not only is the capability of LTP to transfer AmpB from HDL to LDL diminished, but AmpB remains retained with only the HDL fraction. However, when liposomal nystatin is incubated in plasma, over 50% of nystatin distributes with HDLs. Over time, nystatin redistributes from HDL to the lipoprotein-deficient plasma fraction, which is composed of mainly aqueous plasma proteins. The lipid composition selected for the drug appears to be a vital constituent in regulating the drug's interaction with biological fluids. Furthermore, liposome (or liposomal particle) size, fluidity, and other physiochemical characteristics also play a role in altering the pharmacokinetics and pharmacological effects of lipid-based drug formulations. Armed with this understanding, a rational approach to clinical development of these formulations could be facilitated.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/bf01575125", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1093599", 
            "issn": [
              "0934-9723", 
              "1435-4373"
            ], 
            "name": "European Journal of Clinical Microbiology & Infectious Diseases", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "16"
          }
        ], 
        "keywords": [
          "low-density lipoprotein", 
          "amphotericin B", 
          "plasma lipoprotein lipid composition", 
          "lipoprotein lipid composition", 
          "high-density lipoprotein fraction", 
          "lipoprotein-deficient plasma (LPDP) fractions", 
          "infected patients", 
          "drug interactions", 
          "healthy volunteers", 
          "pharmacological effects", 
          "clinical development", 
          "lipoprotein fractions", 
          "HDL fraction", 
          "plasma lipoproteins", 
          "different pharmacokinetics", 
          "liposomal nystatin", 
          "infectious diseases", 
          "plasma fraction", 
          "AmpB", 
          "patients", 
          "pharmacokinetics", 
          "plasma proteins", 
          "HDL", 
          "lipoprotein", 
          "lipid-based drug formulations", 
          "nystatin", 
          "rational approach", 
          "drug formulations", 
          "transfer protein", 
          "HDLs", 
          "lipid composition", 
          "dyslipidemia", 
          "pharmacodynamics", 
          "cancer", 
          "disease", 
          "lipid transfer protein", 
          "volunteers", 
          "drugs", 
          "LTP", 
          "plasma", 
          "protein", 
          "biological fluids", 
          "animals", 
          "liposome size", 
          "phospholipids", 
          "incubation", 
          "fraction", 
          "liposomes", 
          "role", 
          "time", 
          "vital constituents", 
          "effect", 
          "physiochemical characteristics", 
          "fluid", 
          "changes", 
          "development", 
          "interaction", 
          "constituents", 
          "formulation", 
          "understanding", 
          "characteristics", 
          "compounds", 
          "polyenes", 
          "size", 
          "fluidity", 
          "redistributes", 
          "redistribution", 
          "approach", 
          "composition", 
          "system", 
          "behavior", 
          "biological systems", 
          "diversity", 
          "capability", 
          "example"
        ], 
        "name": "Diversity of lipid-based polyene formulations and their behavior in biological systems", 
        "pagination": "81-92", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1053583750"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf01575125"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9063678"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf01575125", 
          "https://app.dimensions.ai/details/publication/pub.1053583750"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:48", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_290.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/bf01575125"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01575125'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01575125'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01575125'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01575125'


     

    This table displays all metadata directly associated to this object as RDF triples.

    210 TRIPLES      21 PREDICATES      117 URIs      104 LITERALS      18 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf01575125 schema:about N00fa247df59a47e38371271a5d78b68a
    2 N092007186dd941bcbada20b22ef768f1
    3 N1798ab53fe3e49db9756506897208a69
    4 N397d444f9f5743bf827ca6ebd93161f1
    5 N39c33cbc39df48428bcb106f4f4d682b
    6 N82d4f44cf2b244ebae950c2c8b5f2552
    7 Nb213adfe444a4ad59735dba3d3fdd831
    8 Nc90d8d81823442e3a33c5c9db72ce017
    9 Nda4c8daeb02b455ea8f95fda98215e67
    10 Ne18d44883eef4bc394c7bde1f4c2afd9
    11 Nf4dda07028de4008b0b097c091bd8256
    12 anzsrc-for:11
    13 anzsrc-for:1101
    14 schema:author Na18ee9cdc74e4f66af6b73cb588f26ee
    15 schema:citation sg:pub.10.1007/978-1-4684-4241-0_11
    16 sg:pub.10.1007/bf01939693
    17 sg:pub.10.1007/bf02795249
    18 sg:pub.10.1038/nbt1283-869
    19 sg:pub.10.2165/00003088-199223040-00004
    20 schema:datePublished 1997-01
    21 schema:datePublishedReg 1997-01-01
    22 schema:description Patients with cancer and infectious diseases often display dyslipidemias that result in changes in their plasma lipoprotein-lipid composition. It is likely that the interactions of liposomal polyenes with plasma lipoproteins may be responsible for the far different pharmacokinetics and pharmacodynamics of these compounds when they are administered to infected patients rather than to animals or healthy volunteers. Amphotericin B (AmpB) and nystatin are examples of such polyenes. Amphotericin B initially distributes with the high-density lipoprotein (HDL) fraction upon incubation in plasma. Over time, AmpB redistributes from HDLs to low-density lipoproteins (LDLs). This redistribution appears to be regulated by lipid transfer protein. However, when AmpB is incorporated into liposomes composed of negatively or positively charged phospholipids, not only is the capability of LTP to transfer AmpB from HDL to LDL diminished, but AmpB remains retained with only the HDL fraction. However, when liposomal nystatin is incubated in plasma, over 50% of nystatin distributes with HDLs. Over time, nystatin redistributes from HDL to the lipoprotein-deficient plasma fraction, which is composed of mainly aqueous plasma proteins. The lipid composition selected for the drug appears to be a vital constituent in regulating the drug's interaction with biological fluids. Furthermore, liposome (or liposomal particle) size, fluidity, and other physiochemical characteristics also play a role in altering the pharmacokinetics and pharmacological effects of lipid-based drug formulations. Armed with this understanding, a rational approach to clinical development of these formulations could be facilitated.
    23 schema:genre article
    24 schema:isAccessibleForFree false
    25 schema:isPartOf N443289b316b24ed79ad31e33bc78aee4
    26 Ne053b1e7fe1c44c2a45b6b3a4c5971c1
    27 sg:journal.1093599
    28 schema:keywords AmpB
    29 HDL
    30 HDL fraction
    31 HDLs
    32 LTP
    33 amphotericin B
    34 animals
    35 approach
    36 behavior
    37 biological fluids
    38 biological systems
    39 cancer
    40 capability
    41 changes
    42 characteristics
    43 clinical development
    44 composition
    45 compounds
    46 constituents
    47 development
    48 different pharmacokinetics
    49 disease
    50 diversity
    51 drug formulations
    52 drug interactions
    53 drugs
    54 dyslipidemia
    55 effect
    56 example
    57 fluid
    58 fluidity
    59 formulation
    60 fraction
    61 healthy volunteers
    62 high-density lipoprotein fraction
    63 incubation
    64 infected patients
    65 infectious diseases
    66 interaction
    67 lipid composition
    68 lipid transfer protein
    69 lipid-based drug formulations
    70 lipoprotein
    71 lipoprotein fractions
    72 lipoprotein lipid composition
    73 lipoprotein-deficient plasma (LPDP) fractions
    74 liposomal nystatin
    75 liposome size
    76 liposomes
    77 low-density lipoprotein
    78 nystatin
    79 patients
    80 pharmacodynamics
    81 pharmacokinetics
    82 pharmacological effects
    83 phospholipids
    84 physiochemical characteristics
    85 plasma
    86 plasma fraction
    87 plasma lipoprotein lipid composition
    88 plasma lipoproteins
    89 plasma proteins
    90 polyenes
    91 protein
    92 rational approach
    93 redistributes
    94 redistribution
    95 role
    96 size
    97 system
    98 time
    99 transfer protein
    100 understanding
    101 vital constituents
    102 volunteers
    103 schema:name Diversity of lipid-based polyene formulations and their behavior in biological systems
    104 schema:pagination 81-92
    105 schema:productId N95e4dd51332643319df3e04a1027d879
    106 Ncf0f9824ecbc4148acea3bafe0e4c992
    107 Nd5123d82e3f94b64908acac68fc21d90
    108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053583750
    109 https://doi.org/10.1007/bf01575125
    110 schema:sdDatePublished 2022-09-02T15:48
    111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    112 schema:sdPublisher N87fdeb43e50b41478eab15a6e67fd2a4
    113 schema:url https://doi.org/10.1007/bf01575125
    114 sgo:license sg:explorer/license/
    115 sgo:sdDataset articles
    116 rdf:type schema:ScholarlyArticle
    117 N00fa247df59a47e38371271a5d78b68a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Immunocompromised Host
    119 rdf:type schema:DefinedTerm
    120 N092007186dd941bcbada20b22ef768f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Nystatin
    122 rdf:type schema:DefinedTerm
    123 N1798ab53fe3e49db9756506897208a69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    124 schema:name Anti-Bacterial Agents
    125 rdf:type schema:DefinedTerm
    126 N397d444f9f5743bf827ca6ebd93161f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Lipoproteins
    128 rdf:type schema:DefinedTerm
    129 N39c33cbc39df48428bcb106f4f4d682b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    130 schema:name Humans
    131 rdf:type schema:DefinedTerm
    132 N443289b316b24ed79ad31e33bc78aee4 schema:volumeNumber 16
    133 rdf:type schema:PublicationVolume
    134 N82d4f44cf2b244ebae950c2c8b5f2552 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Kidney
    136 rdf:type schema:DefinedTerm
    137 N87fdeb43e50b41478eab15a6e67fd2a4 schema:name Springer Nature - SN SciGraph project
    138 rdf:type schema:Organization
    139 N95e4dd51332643319df3e04a1027d879 schema:name dimensions_id
    140 schema:value pub.1053583750
    141 rdf:type schema:PropertyValue
    142 N9ef395cafa9544a1a2fba427ac7ae123 rdf:first sg:person.0650504273.00
    143 rdf:rest rdf:nil
    144 Na18ee9cdc74e4f66af6b73cb588f26ee rdf:first sg:person.0666655515.32
    145 rdf:rest N9ef395cafa9544a1a2fba427ac7ae123
    146 Nb213adfe444a4ad59735dba3d3fdd831 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Phagocytes
    148 rdf:type schema:DefinedTerm
    149 Nc90d8d81823442e3a33c5c9db72ce017 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Antifungal Agents
    151 rdf:type schema:DefinedTerm
    152 Ncf0f9824ecbc4148acea3bafe0e4c992 schema:name doi
    153 schema:value 10.1007/bf01575125
    154 rdf:type schema:PropertyValue
    155 Nd5123d82e3f94b64908acac68fc21d90 schema:name pubmed_id
    156 schema:value 9063678
    157 rdf:type schema:PropertyValue
    158 Nda4c8daeb02b455ea8f95fda98215e67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Mycoses
    160 rdf:type schema:DefinedTerm
    161 Ne053b1e7fe1c44c2a45b6b3a4c5971c1 schema:issueNumber 1
    162 rdf:type schema:PublicationIssue
    163 Ne18d44883eef4bc394c7bde1f4c2afd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Amphotericin B
    165 rdf:type schema:DefinedTerm
    166 Nf4dda07028de4008b0b097c091bd8256 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Liposomes
    168 rdf:type schema:DefinedTerm
    169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    170 schema:name Medical and Health Sciences
    171 rdf:type schema:DefinedTerm
    172 anzsrc-for:1101 schema:inDefinedTermSet anzsrc-for:
    173 schema:name Medical Biochemistry and Metabolomics
    174 rdf:type schema:DefinedTerm
    175 sg:journal.1093599 schema:issn 0934-9723
    176 1435-4373
    177 schema:name European Journal of Clinical Microbiology & Infectious Diseases
    178 schema:publisher Springer Nature
    179 rdf:type schema:Periodical
    180 sg:person.0650504273.00 schema:affiliation grid-institutes:grid.240145.6
    181 schema:familyName Lopez-Berestein
    182 schema:givenName G.
    183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650504273.00
    184 rdf:type schema:Person
    185 sg:person.0666655515.32 schema:affiliation grid-institutes:grid.17091.3e
    186 schema:familyName Wasan
    187 schema:givenName K. M.
    188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666655515.32
    189 rdf:type schema:Person
    190 sg:pub.10.1007/978-1-4684-4241-0_11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041284496
    191 https://doi.org/10.1007/978-1-4684-4241-0_11
    192 rdf:type schema:CreativeWork
    193 sg:pub.10.1007/bf01939693 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040111814
    194 https://doi.org/10.1007/bf01939693
    195 rdf:type schema:CreativeWork
    196 sg:pub.10.1007/bf02795249 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023737788
    197 https://doi.org/10.1007/bf02795249
    198 rdf:type schema:CreativeWork
    199 sg:pub.10.1038/nbt1283-869 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026993837
    200 https://doi.org/10.1038/nbt1283-869
    201 rdf:type schema:CreativeWork
    202 sg:pub.10.2165/00003088-199223040-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041292032
    203 https://doi.org/10.2165/00003088-199223040-00004
    204 rdf:type schema:CreativeWork
    205 grid-institutes:grid.17091.3e schema:alternateName Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, V6T 1Z3, Vancouver, British Columbia, Canada
    206 schema:name Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, V6T 1Z3, Vancouver, British Columbia, Canada
    207 rdf:type schema:Organization
    208 grid-institutes:grid.240145.6 schema:alternateName Section of Immunobiology and Drug Carriers, Department of Bioimmunotherapy, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA
    209 schema:name Section of Immunobiology and Drug Carriers, Department of Bioimmunotherapy, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA
    210 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...